Dont go looking for a buyout anytime soon. 7 opioid ARTs in development and the 3 new hires tells me Elite will try to develop and get out as many opioid ARTs as possible. The more they get out there the more valued this company becomes for a buy out. That was Jerrys plan as discussed in the June conference call of 2012. Fast forward to now. Nasrat Hakim is guiding this company toward that goal.
From the FDA:
We have said that a class-wide requirement is not feasible or in the interests of public health at this time.
But the agency did give some signal that it may eventually call for all opioids to have abuse-deterrent properties.
If the above should eventually happen how valuable would this company become? And given Hikes conservative number crunching for even a 10% capture of the prescription opioid market by Elite what would the share price be if the FDA required all prescription opioids to have ADT/ART properties included? Elite being the best currently out there.
Lots of companies would either have to license or partner with Elite.
So dont be too hasty with the buyout scenario. Could happen but then again there are also other forces in motion here.
Time will tell.
As for the high risk investing in Elite... that was over in 2011-2012 when the company turned itself around under Jerry.
Now that Elite is no longer a going concern... the risk has become even smaller. Elite is on the cusp of getting approval for their ADT/ART technology by the FDA. The stakes are very slight at this point. Nasrat is hardly a high roller. His moves are well planned and calculated by a man who knows exactly what he is doing. He has surrounded himself with an excellent staff and recently bolstered this staff with regulatory, legal, and formulations/analytical personnel whose backgrounds suggest a good deal of experience with Big Pharma.
Cannot stop what is to come. ART is coming from Elite to an opioid nearby.
News 
Market Data 
Discover 
